Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
Volume
9.34 M
Value Traded
75.91 M
Short % Float
3.07%
Days to Cover
1.4
0%Week
0%1 Month
0%3 Month
0%6 Month
0%5 Year
-98.56%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
564.95 M
EPS (TTM)
-0.73
P/E Ratio
-
Ent. Value
501.51 M
Total Shares
69.23 M
Float Shares
57.33 M
Insiders
17.19%
Institutions
68.07%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
RGLS Catalyst Timeline
Dated clinical, regulatory and corporate events for Regulus Therapeutics Inc.
Past FDA Catalysts and PDUFA Decisions
How RGLS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
2
Drugs Scored
rNPV / MCap
Top Drug
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| RGLS4326 Small moleculeCompletedNCT04536688 | Polycystic Kidney Disease, Autosomal Dominant | Phase 1 | COMPLETED | 19 | Nov 12, 2021 | ||||||
| RGLS8429 Small moleculeCompletedNCT05521191 | Autosomal Dominant Polycystic Kidney Disease | Phase 1 | COMPLETED | 68 | Mar 27, 2025 |
Clinical Trial Results
Readouts, endpoints and source filings for every RGLS program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| farabursen | Autosomal Dominant Polycystic Kidney Disease | Phase 1b | 2025-03-27 | Patients receiving 300 mg farabursen demonstrated a mean halting of height-adjusted total kidney volume (htTKV) growth over 4 months.; Exploratory analysis of patients from high-dose cohorts demonstrates statistical significance in htTKV change compared to a large cohort of historical placebo-treated patients.Read More | Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Collier Kathryn JDirector | Option | 2,604 65,240 held | $9.90 | 06/17/2025 |
Hedge Fund 13F Activity
Hedge Funds invested in RGLS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| NEA Management Company, LLC | 0.9 % (50 %) | 11.32 M | 6.47 M |
Ownership Trends
RGLS Short Interest
Shares sold short, counted twice a month.
3.07%
Short % of Float
of tradable shares sold short
1.8M
Shares Sold Short
-15.8% vs prior count
1.4 Low
Days to Cover
trading days of normal volume to buy every short share back
1.3M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How RGLS ranks across every disease it competes in
Competitive Position is a premium feature
See how RGLS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialRGLS News
About Regulus Therapeutics Inc.
BIOPHARMAWATCH ELITE PLUS
Trade the next RGLS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime